The COVID-19 Patient Confidence Study, a weekly measure of consumer attitudes and behavior, shows that consumer confidence is at the highest levels since the onset of COVID-19.
72% of patients have reported that they are not delaying a doctor visit to discuss a condition. In addition, the majority of patients expect to go to the HCP in the next two months or sooner, while only 37% expected to go in the next two months on April 30.
86% of consumers are comfortable visiting healthcare providers, over twice the confidence of visiting a restaurant or the 36% comfortable attending a public gathering such as a rock concert or sports event.
Physician search has significantly increased across the country from late March. For example, in Nevada, there was an increase of 129%; in Texas, there was an increase of 111%; and in New York an increase of 114%.
The research also shows that telemedicine has played an important role in delivering care. According to the survey, 30% of respondents have participated in telemedicine in the past 3 months and 83% are open to interacting with their care provider virtually.
Infosurv Research is a boutique research agency based in Atlanta, GA.
Myosin Therapeutics granted USD2m funding from Florida Department of Health
Clover Biopharmaceuticals reports positive US Phase I data for RSV re-vaccination in older adults
Hope Medicine reports first patient dosed in Phase III trial of HMI-115
Akeso's Phase II trials of AK146D1 and AK138D1 approved in China
Insilico Medicine and ASKA Pharmaceutical expand partnership on women's health targets
Pharming secures Japan approval for Joenja in rare immune disorder treatment
BioArctic and Eisai present new lecanemab and exidavnemab data at AD/PD 2026
HUTCHMED launches Phase III trial of HMPL-760 for DLBCL in China
Pfizer and Valneva report strong Phase 3 results for Lyme disease vaccine candidate
Futura Medical reports positive home user test results for Eroxon and Intense variant
GSK secures Japan Orphan Drug status for lung cancer ADC
TheraCryf advances lead addiction programme to final preclinical stage
Dizal meets primary endpoint in Phase 3 study of ZEGFROVY (sunvozertinib) monotherapy
Innovent Biologics reports first participant dosed in tigulixostat Phase 3 study